ArticleWorld journal of urology2013
Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control.
Article in World journal of urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.Prostate cancer and prostatic diseases · 2019Trial
- Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer.Current oncology (Toronto, Ont.) · 2021Review
- Cardiovascular Toxicities of Androgen Deprivation Therapy.Current treatment options in oncology · 2021Review
- Elevated Serum FGG Levels Prognosticate and Promote the Disease Progression in Prostate Cancer.Frontiers in genetics · 2021Article
- Systemic Coagulation Markers Especially Fibrinogen Are Closely Associated with the Aggressiveness of Prostate Cancer in Patients Who Underwent Transrectal Ultrasound-Guided Prostate Biopsy.Disease markers · 2021Article
- Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients.Chinese medical journal · 2019Article
- Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer.Current treatment options in cardiovascular medicine · 2017Review
- Albumin and Fibrinogen Combined Prognostic Grade Predicts Prognosis of Patients with Prostate Cancer.Journal of Cancer · 2017Article
- Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy.Prostate cancer and prostatic diseases · 2016Article
- Androgen deprivation therapy for prostate cancer: friend or foe to the cardiovascular system?World journal of urology · 2016Article
- The association of an elevated plasma fibrinogen level with cancer-specific and overall survival in prostate cancer patients.World journal of urology · 2015Article
- Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer.Journal of the American Heart Association · 2015Article
- Cardiovascular effects of hormone therapy for prostate cancer.Drug, healthcare and patient safety · 2015Review
- Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: A prospective, longitudinal study.Canadian Urological Association journal = Journal de l'Association des urologues du CanadaArticle
- Lipid Status During Combined Treatment in Prostate Cancer Patients.American journal of men's healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAndrogen deprivation therapy (ADT) for prostate cancer (PCa) may increase peripheral insulin resistance, induce type 2 diabetes, change body composition, and alter lipoprotein profile. Some studies have reported an association between ADT and increased risk of cardiovascular events. It is known that serum level of fibrinogen (SF) is associated with coronary artery disease and increased cardiovascular risk (CVR). The aim of this study is to determine the increase in SF and C-reactive protein (CRP) of PCa patients on ADT.
methodsNinety-seven patients with locally advanced PCa (study group) were analyzed [mean age 73.4 years ± 6.3 SD, mean prostate specific antigen (PSA) 15.4 ng/ml ± 7.5 SD]. They were examined with blood chemistry including serum cholesterol (CHL), high density lipoproteins (HDL), low density lipoproteins (LDL), very low density lipoproteins, triacylglycerol (TAG), serum fibrinogen (FB), CRP and serum fasting glucose (SFG), serum testosterone, free testosterone at baseline, and after 12 months of ADT.
resultsPatients after 12 months of ADT (study group) had significantly higher overall serum CHL (p < 0.001), higher LDL (p = 0.01), higher FB (p < 0.001), higher serum SFG (p = 0.03) in comparison with the control group. Increase in HDL (p = 0.245) and CRP (p = 0.1) was not significant. Two patients from the study group were diagnosed with new-onset diabetes.
conclusionsThis is the first study that demonstrates the significant increase in FB in PCa patients on ADT, while CRP as inflammatory marker did not increase. Elevation of SF may contribute to increased CVR in PCa patients. Further prospective studies are warranted to confirm this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.